Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells

B. Scappini, F. Onida, H. M. Kantarjian, L. Dong, S. Verstovsek, M. J. Keating, M. Beran

Research output: Contribution to journalArticle

Abstract

STI571 is a 2-phenylalaminopyrimidine derivative that inhibits c-abl, Bcr-Abl, and platelet-derived growth factor receptor tyrosine kinases. Recently, inhibition of stem cell factor (SCF)-induced c-kit phosphorylation and cell proliferation by STI571 was reported in the human myeloid cell line MO7e. Because ∼70% of acute myelogenous leukemia (AML) cases are c-kit positive, we evaluated in vitro effects of STI571 on c-kit-positive cell lines and primary AML blast cells. At concentrations >5 μM, the drug marginally inhibited SCF-independent proliferation of cell lines and most of AML blasts. Treatment of AML cells with cytarabine and STI571 showed synergistic effect at low concentrations. Western blotting analysis documented a distinct band of Mr 145,000 specific for c-kit in cell lines and in AML samples. There was no correlation between the level of the c-kit expression evaluated by Western blotting and percentage of c-kit-positive blasts as measured by flow cytometry, Neither in cell lines nor in primary AML cells, c-kit autophosphorylation was detectable under standard growth conditions. SCF-induced phosphorylation of c-kit in MO7e cells was inhibited by STI571. In a c-kit-positive AML-4 cell line, as well as in AML samples, c-kit phosphorylation was not induced by SCF exposure, suggesting that in these cases, the receptor could not be functionally activated. In conclusion, with the exception of MO7e, SCF did not induce phosphorylation of c-kit, and cell proliferation was not modulated in the presence of STI571. We did not detect any SCF-independent c-kit phosphorylation in our experimental systems. Consequently, STI571 exerted only a limited inhibitory effect on the cell growth.

Original languageEnglish
Pages (from-to)3884-3893
Number of pages10
JournalClinical Cancer Research
Volume7
Issue number12
Publication statusPublished - 2001

Fingerprint

Acute Myeloid Leukemia
Stem Cell Factor
Signal Transduction
Cell Line
Phosphorylation
Western Blotting
Cell Proliferation
Cytarabine
Myeloid Cells
Growth
Imatinib Mesylate
Flow Cytometry
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Scappini, B., Onida, F., Kantarjian, H. M., Dong, L., Verstovsek, S., Keating, M. J., & Beran, M. (2001). Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clinical Cancer Research, 7(12), 3884-3893.

Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. / Scappini, B.; Onida, F.; Kantarjian, H. M.; Dong, L.; Verstovsek, S.; Keating, M. J.; Beran, M.

In: Clinical Cancer Research, Vol. 7, No. 12, 2001, p. 3884-3893.

Research output: Contribution to journalArticle

Scappini, B, Onida, F, Kantarjian, HM, Dong, L, Verstovsek, S, Keating, MJ & Beran, M 2001, 'Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells', Clinical Cancer Research, vol. 7, no. 12, pp. 3884-3893.
Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ et al. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clinical Cancer Research. 2001;7(12):3884-3893.
Scappini, B. ; Onida, F. ; Kantarjian, H. M. ; Dong, L. ; Verstovsek, S. ; Keating, M. J. ; Beran, M. / Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 12. pp. 3884-3893.
@article{9dac712abf9f45198c86ddcffac48cac,
title = "Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells",
abstract = "STI571 is a 2-phenylalaminopyrimidine derivative that inhibits c-abl, Bcr-Abl, and platelet-derived growth factor receptor tyrosine kinases. Recently, inhibition of stem cell factor (SCF)-induced c-kit phosphorylation and cell proliferation by STI571 was reported in the human myeloid cell line MO7e. Because ∼70{\%} of acute myelogenous leukemia (AML) cases are c-kit positive, we evaluated in vitro effects of STI571 on c-kit-positive cell lines and primary AML blast cells. At concentrations >5 μM, the drug marginally inhibited SCF-independent proliferation of cell lines and most of AML blasts. Treatment of AML cells with cytarabine and STI571 showed synergistic effect at low concentrations. Western blotting analysis documented a distinct band of Mr 145,000 specific for c-kit in cell lines and in AML samples. There was no correlation between the level of the c-kit expression evaluated by Western blotting and percentage of c-kit-positive blasts as measured by flow cytometry, Neither in cell lines nor in primary AML cells, c-kit autophosphorylation was detectable under standard growth conditions. SCF-induced phosphorylation of c-kit in MO7e cells was inhibited by STI571. In a c-kit-positive AML-4 cell line, as well as in AML samples, c-kit phosphorylation was not induced by SCF exposure, suggesting that in these cases, the receptor could not be functionally activated. In conclusion, with the exception of MO7e, SCF did not induce phosphorylation of c-kit, and cell proliferation was not modulated in the presence of STI571. We did not detect any SCF-independent c-kit phosphorylation in our experimental systems. Consequently, STI571 exerted only a limited inhibitory effect on the cell growth.",
author = "B. Scappini and F. Onida and Kantarjian, {H. M.} and L. Dong and S. Verstovsek and Keating, {M. J.} and M. Beran",
year = "2001",
language = "English",
volume = "7",
pages = "3884--3893",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells

AU - Scappini, B.

AU - Onida, F.

AU - Kantarjian, H. M.

AU - Dong, L.

AU - Verstovsek, S.

AU - Keating, M. J.

AU - Beran, M.

PY - 2001

Y1 - 2001

N2 - STI571 is a 2-phenylalaminopyrimidine derivative that inhibits c-abl, Bcr-Abl, and platelet-derived growth factor receptor tyrosine kinases. Recently, inhibition of stem cell factor (SCF)-induced c-kit phosphorylation and cell proliferation by STI571 was reported in the human myeloid cell line MO7e. Because ∼70% of acute myelogenous leukemia (AML) cases are c-kit positive, we evaluated in vitro effects of STI571 on c-kit-positive cell lines and primary AML blast cells. At concentrations >5 μM, the drug marginally inhibited SCF-independent proliferation of cell lines and most of AML blasts. Treatment of AML cells with cytarabine and STI571 showed synergistic effect at low concentrations. Western blotting analysis documented a distinct band of Mr 145,000 specific for c-kit in cell lines and in AML samples. There was no correlation between the level of the c-kit expression evaluated by Western blotting and percentage of c-kit-positive blasts as measured by flow cytometry, Neither in cell lines nor in primary AML cells, c-kit autophosphorylation was detectable under standard growth conditions. SCF-induced phosphorylation of c-kit in MO7e cells was inhibited by STI571. In a c-kit-positive AML-4 cell line, as well as in AML samples, c-kit phosphorylation was not induced by SCF exposure, suggesting that in these cases, the receptor could not be functionally activated. In conclusion, with the exception of MO7e, SCF did not induce phosphorylation of c-kit, and cell proliferation was not modulated in the presence of STI571. We did not detect any SCF-independent c-kit phosphorylation in our experimental systems. Consequently, STI571 exerted only a limited inhibitory effect on the cell growth.

AB - STI571 is a 2-phenylalaminopyrimidine derivative that inhibits c-abl, Bcr-Abl, and platelet-derived growth factor receptor tyrosine kinases. Recently, inhibition of stem cell factor (SCF)-induced c-kit phosphorylation and cell proliferation by STI571 was reported in the human myeloid cell line MO7e. Because ∼70% of acute myelogenous leukemia (AML) cases are c-kit positive, we evaluated in vitro effects of STI571 on c-kit-positive cell lines and primary AML blast cells. At concentrations >5 μM, the drug marginally inhibited SCF-independent proliferation of cell lines and most of AML blasts. Treatment of AML cells with cytarabine and STI571 showed synergistic effect at low concentrations. Western blotting analysis documented a distinct band of Mr 145,000 specific for c-kit in cell lines and in AML samples. There was no correlation between the level of the c-kit expression evaluated by Western blotting and percentage of c-kit-positive blasts as measured by flow cytometry, Neither in cell lines nor in primary AML cells, c-kit autophosphorylation was detectable under standard growth conditions. SCF-induced phosphorylation of c-kit in MO7e cells was inhibited by STI571. In a c-kit-positive AML-4 cell line, as well as in AML samples, c-kit phosphorylation was not induced by SCF exposure, suggesting that in these cases, the receptor could not be functionally activated. In conclusion, with the exception of MO7e, SCF did not induce phosphorylation of c-kit, and cell proliferation was not modulated in the presence of STI571. We did not detect any SCF-independent c-kit phosphorylation in our experimental systems. Consequently, STI571 exerted only a limited inhibitory effect on the cell growth.

UR - http://www.scopus.com/inward/record.url?scp=0035679772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035679772&partnerID=8YFLogxK

M3 - Article

C2 - 11751479

AN - SCOPUS:0035679772

VL - 7

SP - 3884

EP - 3893

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -